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Sir,
The recent paper of Carpenter et al (2006b) in your journal
identified hnRNP K as being overexpressed in colorectal cancer by
proteomics, which has been confirmed by immunohistochemistry
and tissue microarray analysis. Their study also showed that
hnRNP K had an aberrant subcellular localisation in cancer cells.
Although there were previous reports by Moumen et al (2005),
suggesting that, in response to DNA damage, p53 inhibits hnRNP
K ubiquitin-dependent proteasomal degradation, the study by
Carpenter et al (2006a) could not, however, find any correlation
between the expression of hnRNP K and p53 in colorectal cancer
cells. We note the above observations with interest, as hnRNP K
has a role in tumorigenesis and its expression has been found to be
upregulated in several other cancers, including those of lungs and
liver (Carpenter et al, 2006a). Our pilot study with 26 oral cancer
patients has also recorded the significant upregulation (Po0.001)
of hnRNP K mRNA compared with normal oral tissue specimens
using quantitative real-time RT–PCR (Figure 1A). The DCT of
hnRNP K mRNA in cancer tissues (mean7s.d., 2.673.8) was
significantly (Po0.001) lower than that in the corresponding
normal tissues (mean7s.d., 5.4872.3). As such, the increase in the
expression of hnRNP K was about 56-fold in oral SCC compared to
the normal oral epithelium. Among the 26 oral SCC patients, 11, 12
and 3 patients were examined as having well, moderately and
poorly differentiated SCC, respectively. The average DCT value for
well-differentiated SCC group was 3.2673.6, whereas for moder-
ately and poorly differentiated group is 2.1274.05, that is, the
expression of hnRNP K in well-differentiated SCC group was lower
than the moderate and poorly differentiated SCC group
(Figure 1B), but significant correlation between histological grades
of differentiation and hnRNP K mRNA expression could not be
predicted, a larger sample size is needed to decide upon true
correlation. Furthermore, to investigate the correlation between
hnRNP K and p53 in oral cancer, full cDNA of p53 was transiently
transfected in an oral cancer cell line. The level of p53 achieved by
transient transfection was significantly higher than its endogenous
level in mock-transfected cells. Increased expression of p53 in
transfected cells did not, however, alter the expression of hnRNP
K, which therefore corroborate with the data presented by
Carpenter et al (2006b) for colorectal cancer cells.
We hope subsequent studies with immunohistochemistry and
western blotting on normal and oral cancer tissues with larger
sample sizes will strengthen and validate our understanding the
role of hnRNP K in cancer.
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Figure 1 (A) Wide box representation of hnRNP K mRNA expression in cancerous and noncancerous oral tissues. Cancer tissues showed significantly
lower level of DCT or higher level of hnRNP K mRNA expression levels compared to noncancerous tissues (Po0.001). (B) Relative level of hnRNP K
mRNA expression in different histological grades of oral SCC with respect to normal oral tissue. W.D, M.D-P.D represent well, moderately to poorly
differentiated oral SCC tissues. Values are means and s.d. from n¼15 (M.DþP.D) and n¼11(W.D) samples.
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